TRxADE Group Reports First Quarter 2020 Financial Results

Q1 2020 Revenues Increase 46% to $2.2 Million; Drives Net Income Increase of 44% to $0.2 Million

TAMPA, FL, May 04, 2020 (GLOBE NEWSWIRE) -- Trxade Group, Inc., (NASDAQ: MEDS) (“Trxade” or the “Company”), an integrated telehealth, drug procurement, delivery and online healthcare marketplace, today reported its financial results for the first quarter ended March 31, 2020.

Select Financial Highlights:

  Three Months Ended March 31, Year-over-Year  
  2020  2019  % Change 
Revenues $2.2 million $1.5 million  46%
Gross Profit $1.6 million $1.1 million  43%
Gross Margin 74.4% 75.8%  (1.4)%
Net Income (Loss) $0.2 million $0.1 million  44%
Adj. EBITDA (non-GAAP)1 $0.3 million $0.2 million  58%
1) Adjusted EBITDA is a non-GAAP financial measure and is described in relation to its most directly comparable GAAP measure under “Use of Non-GAAP Financial Information” below.

Recent Highlights:

 The Company continued to expand its trading platform organically, with 305 new independent pharmacies registered in Q1 2020
 Average purchases per pharmacy increased on the Trxade platform by 13.7% in the first quarter of 2020, when compared to the same year ago quarter
 The Company secured first contract with an employer to supply COVID-19 rapid test kits for its employees and families, which provides a diagnosis within 15 minutes at point of care (POCT) with no additional instrumentation needed
 Filed for an Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) in collaboration with its partner’s manufacture of the SARS-CoV-2 IgM/IgG Antibody Rapid Test Kits
 Uplisted to Nasdaq Capital Market under the new trading symbol “MEDS” in February 2020
 Received gross proceeds of approximately $5.99 million through an underwritten public stock offering with institutional and accredited investors
 Engaged MZ Group to lead investor relations and shareholder communication program

Management Commentary

“We demonstrated outstanding performance in the first quarter as we reported 46% growth in revenues and exceeded expectations on metrics despite COVID-19,” said Suren Ajjarapu, Chairman and CEO of Trxade Group. “Our diversified growth strategies are driving strong growth across all subsidiaries, including new services and products that directly address the coronavirus pandemic,” further stated Mr. Ajjarapu.

“We have now secured our first employer, a midsized Tampa law firm, to supply COVID-19 rapid test kits to their employees, which will promote a safer working environment and increase awareness of exposure risk. One of our subsidiaries has also begun offering a new monthly subscription bundle at a rate of $19.95 per month, which includes an option of three (3) teleconferencing premium visits per month, as well as free prescription delivery service. We are excited to be taking part in the effort to address COVID-19 and believe we can make a difference in decreasing its spread through testing,” stated Mr. Ajjarapu.

“During the first quarter we took strategic measures to enhance our corporate position, uplisting our common stock to the Nasdaq Capital Market and engaging an investor relations firm to implement a comprehensive capital markets strategy. We also completed an underwritten public stock offering that improved and reinforced our strong balance sheet. Looking forward, we are well positioned with significant momentum to continue growing revenues and income and to meet the increasing demand for our comprehensive service offerings,concluded Mr. Ajjarapu.

First Quarter 2020 Financial Results

Revenues for the first quarter of 2020 increased 46% to $2.2 million, compared to revenue of $1.5 million in the same quarter last year. Sequentially, this represents an increase of 30% when compared to revenues of $1.7 million in the fourth quarter of 2019. The increase in revenue was primarily due to platform sales.

Gross profit in the first quarter of 2020 increased 43% to $1.6 million, or 74.4% of revenues, compared to gross profit of $1.1 million, or 75.8% of revenues, in the same quarter last year. The increase in gross profit was primarily due to platform sales and reduced cost of goods sold.

Operating expenses in the first quarter of 2020 were $1.5 million compared to $1.0 million in the same quarter last year. This increase is primarily due to legal, filing fees and marketing expenses associated with our public offering and uplisting.

Net income in the first quarter of 2020 increased 44% to $0.2 million, or $0.03 per basic share, compared to net income of $0.1 million, or $0.02 per basic share, in the same quarter last year. The increase in net income was primarily due to increased revenue.

Adjusted EBITDA, a non-GAAP financial measure, increased 33% to $0.3 million, compared to $0.2 million in the same quarter last year.

Cash and cash equivalents were $7.7 million as of March 31, 2020, compared with $2.9 million as of December 31, 2019. During the first quarter of 2020, the Company raised gross proceeds of approximately $5.99 million through an underwritten public offering with institutional and accredited investors.

About Trxade Group, Inc.

Headquartered in Tampa, Florida, Trxade Group, Inc. (NASDAQ: MEDS) is an integrated drug procurement, delivery and healthcare platform that enables price transparency and increased profit margins to buyers and sellers of pharmaceuticals, makes Healthcare services affordable and accessible across all 50 states, and steps in to meet today’s immediate demands. Founded in 2010, Trxade Group is comprised of four synergistic operating platforms; 1) the Trxade B2B trading platform with 11,400 registered pharmacies; 2) a licensed virtual Wholesaler; 3) affordable healthcare via its Bonum Health app and web-based telehealth services; and 4) Same Day or Mail Order Pharmacy delivery capabilities via its DelivMeds app featuring Trxade’s extensive nationwide distribution network. For additional information, please visit us at,, and

Supplemental Financial Data

The Attached Selected Supplemental Financial Data tables disclose amounts reflected in our historical financial results and include the balance sheet and results of operations for a comparable period. Trxade utilizes certain financial measures that are not calculated in accordance with generally accepted accounting principles (GAAP) to access its financial performance such as working capital. This presentation should be viewed as a supplement to, and not a substitute for, the results of operations presented on a GAAP basis. Stockholders are encouraged to review the Company’s filings with the Securities and Exchange Commission.

Use of Non-GAAP Financial Information

This earnings release discusses EBITDA and Adjusted EBITDA. These measurements are not recognized in accordance with GAAP and should not be viewed as an alternative to GAAP measures of performance. EBITDA represents net income before interest, taxes, depreciation and amortization. Adjusted EBITDA is defined as EBITDA before stock-based compensation expense and gain (loss) in equity investment. EBITDA and Adjusted EBITDA are presented because we believe they provide additional useful information to investors due to the various noncash items during the period. EBITDA and Adjusted EBITDA have limitations as analytical tools, and you should not consider them in isolation, or as a substitute for analysis of our operating results as reported under GAAP. Some of these limitations are: EBITDA and Adjusted EBITDA do not reflect cash expenditures, future requirements for capital expenditures, or contractual commitments; EBITDA and Adjusted EBITDA do not reflect changes in, or cash requirements for, working capital needs; and EBITDA and Adjusted EBITDA do not reflect the significant interest expense, or the cash requirements necessary to service interest or principal payments, on debt or cash income tax payments. Although depreciation and amortization are noncash charges, the assets being depreciated and amortized will often have to be replaced in the future, and EBITDA and Adjusted EBITDA do not reflect any cash requirements for such replacements. Additionally, other companies in our industry may calculate EBITDA and Adjusted EBITDA differently than Trxade Group, Inc. does, limiting its usefulness as a comparative measure. See also “Reconciliation of Net Income attributable to Trxade Group, Inc., to Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA) and Adjusted EBITDA”, below.

Forward-Looking Statements

This press release may contain forward-looking statements, including information about management’s view of Trxade’s future expectations, plans and prospects, within the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 (the “Act”). In particular, when used in the preceding discussion, the words “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions are intended to identify forward-looking statements within the meaning of the Act, and are subject to the safe harbor created by the Act. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of Trxade, its divisions and concepts to be materially different than those expressed or implied in such statements. These risk factors and others are included from time to time in filings made by Trxade with the Securities and Exchange Commission, including, but not limited to, in the “Risk Factors” sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which we have filed, and file from time to time, with the U.S. Securities and Exchange Commission. These reports are available at Other unknown or unpredictable factors also could have material adverse effects on Trxade’s future results and/or could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. Trxade cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Investor Relations:

Greg Falesnik
Managing Director
MZ Group - MZ North America
(949) 385-6449

Trxade Group, Inc.
Consolidated Balance Sheets
Three Months Ended March 31, 2020 and December 31, 2019

  March 31, 2020  December 31, 2019 
Current Assets        
Cash $7,701,305  $2,871,694 
Accounts Receivable, net  877,097   792,050 
Inventory  368,401   56,761 
Prepaid Assets  267,375   82,452 
Deposits for Inventory purchases  580,800   - 
Total Current Assets  9,794,978   3,802,957 
Property Plant and Equipment, Net  197,242   174,987 
Other Assets        
Deposits  21,636   21,636 
Deferred Offering Costs  -   88,231 
Right of use leased assets  734,075   757,710 
Goodwill  725,973   725,973 
Total Assets $11,473,904  $5,571,494 
Liabilities and Shareholders’ Equity        
Current Liabilities        
Accounts Payable $320,238  $334,614 
Accrued Liabilities  233,560   98,852 
Current Portion Lease Liabilities  90,759   87,350 
Customer Deposits  305,972   - 
Total Current Liabilities  950,529   520,816 
Long Term Liabilities        
Notes Payable – Related Parties  225,000   225,000 
Other Long-term Liabilities – Leases  661,078   685,461 
Total Liabilities  1,836,607   1,431,277 
Shareholders’ Equity        
Series A Preferred Stock, $0.00001 par value; 10,000,000 shares authorized; none issued and outstanding as of March 31, 2020 and December 31, 2019, respectfully  -   - 
Common Stock, $0.00001 par value; 100,000,000 shares authorized; 7,484,370 and 6,539,415 shares issued and outstanding, as of March 31, 2020 and December 31, 2019, respectively  75   65 
Additional Paid-in Capital  17,852,422   12,535,655 
Retained Deficit  (8,215,200)  (8,395,503)
Total Shareholders’ Equity  9,637,297   4,140,217 
Total Liabilities and Shareholders’ Equity $11,473,904  $5,571,494 

Summary of Certain Comparative Financial Information

Balance Sheet Data March 31, 2020  December 31, 2019 
Working Capital (1) $8,844,449  $3,282,141 
Total Assets $11,473,904  $5,571,494 
Long-Term Debt (2) $225,000  $225,000 
Shareholders’ Equity $9,637,297  $4,140,217 

(1) Total current assets for each period minus total current liabilities for each period.
(2) Notes payable, related parties.

Trxade Group, Inc.
Consolidated Statements of Operations
Three Months Ended March 31, 2020 and 2019

  2020  2019 
Revenues, net $2,203,320  $1,512,521 
Cost of Sales  563,184   365,839 
Gross Profit  1,640,136   1,146,682 
Operating Expenses        
Warrants and Options Expense  141,086   35,979 
General and Administrative  1,310,823   938,944 
Total Operating Expenses  1,451,909   974,923 
Operating Income  188,227   171,759 
Loss on Extinguishment of Debt  -   (28,972)
Interest, net  (7,924)  (17,558)
Net Income $180,303  $125,229 
Net Income per Common Share – Basic: $0.03  $0.02 
Net Income per Common Share – Diluted: $0.02  $0.02 
Weighted average Common Shares Outstanding Basic  6,971,438   5,560,695 
Weighted average Common Shares Outstanding Diluted  7,423,680   5,998,056 

Reconciliation of Net Income attributable to Trxade Group, Inc., to Earnings before Interest, Taxes,
Depreciation and Amortization (EBITDA) and Adjusted EBITDA*

  March 31, 2020  March 31, 2019 
Net Income attributable to Trxade Group, Inc. $180,303  $125,229 
Add (Deduct):        
Interest, net  7,924   17,558 
Depreciation and Amortization  1,250   1,250 
EBITDA  189,477   144,037 
Add (Deduct):        
Share in Equity Loss on Investment  -   28,972 
Stock Based Compensation  141,086   35,979 
Adjusted EBITDA $330,563  $208,988 

* EBITDA and Adjusted EBITDA are non-GAAP financial measures. These measurements are not recognized in accordance with GAAP and should not be viewed as an alternative to GAAP measures of performance. See also “Use of Non-GAAP Financial Information”, above.